Home Cart Sign in  
Chemical Structure| 89-71-4 Chemical Structure| 89-71-4

Structure of 89-71-4

Chemical Structure| 89-71-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Morningstar, John Tanner ;

Abstract: Molecular electronics is a continuously growing field which attempts to solve the problem that their solid-state counterparts encounter with continuing to grow smaller while maintaining the same functionality. Although successful molecular electronics have been created, their level of functionality does not yet match solid states. Furthering the field involves elucidating the mechanism of rectification and continuing to grow the library of compounds available. To accomplish this, we have successfully synthesized twenty new alkylsilanes which exhibit rectification behavior. We were able to draw several conclusions about promising scaffolds through examination of terminal groups with electron withdrawing and donating substituents, nitrogen heterocycles, and sterically hindered substituents. Additionally, our compounds were subjected to doping of the selfassembled monolayer devices which we found to benefit rectification. It was hypothesized that adding electron withdrawing groups, large and soft atoms, and groups with non-bonding electrons would also boost rectification. We obtained compounds with R ratios as high as 8500. This value is the highest our group has achieved to date. Biopolymers are commonly used as drug delivery scaffolds due to their safety and resistance to environmental stimuli. Alginate is one such polymer which has garnered increased attention as of late. To improve the properties of alginate for this purpose, we have developed a method to quantitatively modify the backbone of alginate with small molecules via sodium periodate oxidation and reductive amination of the corresponding oxidized product. Examining the difference in modified alginate with a small unsubstituted aromatic ring as well as an aromatic ketone, ester, and carboxylic acid allowed us to determine which molecules are beneficial to environmental pH sensitivity. xiv We successfully synthesized three new quantitatively modified alginates and examined their pH sensitivity using hydrogel beading studies. Each new compound shows distinct pH response; however, our expectations were met as our original benzoic acid modified product still holds the most desirable degradation profile.

Purchased from AmBeed: ; ; ; ; ;

Alternative Products

Product Details of [ 89-71-4 ]

CAS No. :89-71-4
Formula : C9H10O2
M.W : 150.17
SMILES Code : O=C(OC)C1=CC=CC=C1C
MDL No. :MFCD00008428
Boiling Point : No data available
InChI Key :WVWZECQNFWFVFW-UHFFFAOYSA-N
Pubchem ID :33094

Safety of [ 89-71-4 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Computational Chemistry of [ 89-71-4 ] Show Less

Physicochemical Properties

Num. heavy atoms 11
Num. arom. heavy atoms 6
Fraction Csp3 0.22
Num. rotatable bonds 2
Num. H-bond acceptors 2.0
Num. H-bond donors 0.0
Molar Refractivity 42.69
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

26.3 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

2.15
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

2.75
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

1.78
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

2.25
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

2.16
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

2.22

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-2.78
Solubility 0.252 mg/ml ; 0.00168 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-2.96
Solubility 0.166 mg/ml ; 0.0011 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-2.84
Solubility 0.216 mg/ml ; 0.00144 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

Yes
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-5.26 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

1.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

1.11
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 89-71-4 ]

Aryls

Chemical Structure| 4122-56-9

A105884 [4122-56-9]

Methyl 2-formylbenzoate

Similarity: 1.00

Chemical Structure| 23617-71-2

A136167 [23617-71-2]

Methyl 2,4-dimethylbenzoate

Similarity: 1.00

Chemical Structure| 28269-31-0

A201986 [28269-31-0]

Dimethyl 2-methylisophthalate

Similarity: 1.00

Chemical Structure| 4376-18-5

A281507 [4376-18-5]

2-(Methoxycarbonyl)benzoic acid

Similarity: 1.00

Chemical Structure| 15012-36-9

A518470 [15012-36-9]

Methyl 2,3-dimethylbenzoate

Similarity: 1.00

Esters

Chemical Structure| 4122-56-9

A105884 [4122-56-9]

Methyl 2-formylbenzoate

Similarity: 1.00

Chemical Structure| 23617-71-2

A136167 [23617-71-2]

Methyl 2,4-dimethylbenzoate

Similarity: 1.00

Chemical Structure| 28269-31-0

A201986 [28269-31-0]

Dimethyl 2-methylisophthalate

Similarity: 1.00

Chemical Structure| 4376-18-5

A281507 [4376-18-5]

2-(Methoxycarbonyl)benzoic acid

Similarity: 1.00

Chemical Structure| 15012-36-9

A518470 [15012-36-9]

Methyl 2,3-dimethylbenzoate

Similarity: 1.00